Loading...
•
Mar 31, 2020
Checkpoint Therapeutics Q1 2020 Earnings Report
Reported financial results for the first quarter ended March 31, 2020.
Key Takeaways
Checkpoint Therapeutics reported its financial results for the first quarter of 2020, highlighting the progress of cosibelimab and the issuance of a composition of matter patent.
Continued progress with the development of cosibelimab.
FDA confirmed the registration submission pathway for cosibelimab in metastatic cutaneous squamous cell carcinoma (CSCC).
U.S. Patent and Trademark Office issued a composition of matter patent for cosibelimab, providing protection through at least May 2038.
Continued to enroll CSCC patients to support the first marketing application submission.
Forward Guidance
The press release contains forward-looking statements regarding plans to submit BLAs and seek approvals for cosibelimab, the potential differentiation of cosibelimab, the half-life and functional Fc domain of cosibelimab translating into potential enhanced efficacy, statements relating to how long the company believes its cash will fund operations, growth strategy and product development programs.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...